Significant Findings from the RAPIDe-3 Pivotal Study
Pharvaris, a pioneering biopharmaceutical company, has heralded the results of its RAPIDe-3 pivotal study, showcasing the efficacy of deucrictibant, an oral bradykinin B2 receptor antagonist. The primary endpoint was met with remarkable findings: the median time to onset of symptom relief was achieved in a mere 1.28 hours, significantly outpacing placebo results, which registered at well over 12 hours (p<0.0001).
Comprehensive Efficacy Across Endpoints
Every secondary efficacy endpoint also met statistical significance (p<0.0001). Notably, the End of Progression™ was observed at a median time of 17.47 minutes, with complete symptom resolution occurring on average within 11.95 hours of treatment. This underscores the rapid action of deucrictibant, presenting a promising therapeutic option for patients suffering from hereditary angioedema (HAE) attacks.
Well-Tolerated Safety Profile
The study confirmed a well-tolerated safety profile for deucrictibant, with no serious treatment-related adverse events reported. Not only was the median relief time impressively swift, but patients also showed a reduced need for rescue medication–93.2% experienced symptom relief without requiring further treatment within the initial 12 hours.
The Diverse Patient Population of RAPIDe-3
The RAPIDe-3 study included a broad and diverse patient sector, incorporating individuals aged 12 and older, across 24 countries and multiple continents. Participants represented different types of HAE, including type 1 and type 2, and those with normal C1 inhibitor levels, thereby offering a comprehensive view of deucrictibant’s efficacy.
Expert Insights on Study Outcomes
Dr. Marc A. Riedl, the principal investigator for the study, highlighted how the mechanism of bradykinin B2 receptor antagonism is recognized for its effectiveness in treating angioedema. He emphasized that the swift treatment response and early symptom resolution provided by deucrictibant are game-changers for HAE management.
Acknowledgements and Future Directions
Dr. Peng Lu, the Chief Medical Officer of Pharvaris, expressed gratitude to all study participants and support teams, emphasizing their contributions to advancing HAE treatment. Deucrictibant's compelling results signify a vital step towards regulatory applications intended for marketing approval, with plans to submit a New Drug Application (NDA) to the U.S. FDA in the first half of 2026.
Further Research and Developments
An ongoing open-label extension of the study, known as RAPIDe-2 Part B, will continue to assess deucrictibant's treatment efficacy in addressing acute HAE attacks. Pharvaris intends to present more epidemiological and patient experience data at forthcoming medical congresses, further strengthening their commitment to advancing patient care in bradykinin-mediated diseases.
Available Treatment Options
Deucrictibant has been strategically developed as a potent oral small-molecule antagonist. Its aim is manifold: to tackle both the immediate and preventive aspects of bradykinin-mediated angioedema attacks. With two formulations, an immediate-release capsule and an extended-release tablet, Pharvaris is dedicated to providing flexible solutions for patients.
Company Insights and Aspirations
As an organization, Pharvaris is steadfast in its mission to innovate within bradykinin-mediated conditions. The outcomes of the RAPIDe-3 study not only affirm their research but also reinforce their aim to establish a new standard of care through oral therapeutics.
Frequently Asked Questions
What were the main findings of the RAPIDe-3 study?
The study showed that deucrictibant significantly reduced the time to symptom relief, with a median of 1.28 hours versus over 12 hours in the placebo group.
How does deucrictibant work?
Deucrictibant acts as a bradykinin B2 receptor antagonist, which helps alleviate symptoms associated with angioedema.
What is the timeline for Pharvaris's NDA submission?
Pharvaris plans to submit its New Drug Application to the FDA in the first half of 2026.
Is deucrictibant well tolerated?
Yes, the study indicated that deucrictibant has a well-tolerated safety profile without any serious adverse events related to treatment.
What future studies are planned for deucrictibant?
Pharvaris is continuing with the RAPIDe-2 Part B extension study and preparing to present additional data at medical congresses.
